COMPANY
GentiBio, Inc
Funding and NIH signals
- NIH award NIH awarded $1.06M (SBIR Phase II 1R44DK148134-01, new, notice Sep 17, 2026); 4 NIH awards totaling $3.6M in the last 12 months. NIH RePORTER 1R44DK148134-01 (Sep 17, 2026)
Evidence (4 events)
- Sep 17, 2026 · NIH RePORTER 1R44DK148134-01
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R44DK148134-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1061227; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Disease; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1R43NS149828-01
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R43NS149828-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 320037; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Engineered Tissue Treg Therapy for the Treatment of ALS; Organization type: Domestic For-Profits - Aug 24, 2026 · NIH RePORTER 1R44DK148168-01
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R44DK148168-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1066332; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: GNTI-148: an allogeneic islet-specific engineered Treg for treating T1D; Organization type: Domestic For-Profits - Jul 8, 2026 · NIH RePORTER 5R44NS145848-02
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS145848-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 1150749; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44DK148134-01
Timeline
Upcoming milestones
- Jan 30, 2027 (ESTIMATED) · · HLA Demographics Study in Adults With Type 1 Diabetes · NCT06860516
- 2028-02 (ESTIMATED) · Phase 1 · A Study of GNTI-122 in Adults Recently Diagnosed With T1D · NCT06919354
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06860516 | HLA Demographics Study in Adults With Type 1 Diabetes | Not listed | Recruiting | Jun 6, 2025 | Jan 30, 2027 (estimated) |
| NCT06919354 | A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | Recruiting | Sep 3, 2025 | 2028-02 (estimated) |
NIH awards 5
- NIH award 1R44DK148134-01 FY2026: $1,061,227 awarded for that fiscal year; activity R44 (SBIR); PI SASSONE-CORSI, MARTINA; recipient as written: GENTIBIO, INC., CAMBRIDGE, MA. An allogeneic and gut specific Engineere source ↗
- NIH award 1R43NS149828-01 FY2026: $320,037 awarded for that fiscal year; activity R43 (SBIR); PI ZAMMIT, NATHAN WILLIAM; recipient as written: GENTIBIO, INC., CAMBRIDGE, MA. Engineered Tissue Treg Therapy for the Tre source ↗
- NIH award 1R44DK148168-01 FY2026: $1,066,332 awarded for that fiscal year; activity R44 (SBIR); PI UENISHI, GENE ICHIRO; recipient as written: GENTIBIO, INC., CAMBRIDGE, MA. GNTI-148: an allogeneic islet-specific eng source ↗
- NIH award 5R44NS145848-02 FY2026: $1,150,749 awarded for that fiscal year; activity R44 (SBIR); PI ZARIN, PAYAM; recipient as written: GENTIBIO, INC., CAMBRIDGE, MA. Development of Tissue Engineered Tregs as a Treatm source ↗
- NIH award 1R44NS145848-01 FY2025: $1,150,417 awarded for that fiscal year; activity R44 (SBIR); PI ZARIN, PAYAM; recipient as written: GENTIBIO, INC., CAMBRIDGE, MA. Development of Tissue Engineered Tregs as a Treatm source ↗
Raises and investors new
- InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗